BioRestorative Therapies, Inc. · NASDAQ:BRTX

BioRestorative Therapies — Investor Presentation (April 2024)

30 slides from BioRestorative Therapies's investor presentation, April 2024

  1. Slide 1: Regenerative Biology for Healthier Lives

    Regenerative Biology for Healthier Lives Investor Presentation April 2024

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements in this presentation, including the information set forth as to the future financial or operating performance of Biorestorative Therapies, Inc. (the “Company”) that are not current or historical factual statements may constitute “forward-looking” information wit

  3. Slide 3: Fully Integrated Regenerative Medicine Company

    Fully Integrated Regenerative Medicine Company DEVELOPMENT COMMERCIAL ThermoStem BRTX-100 BioCosmeceuticals Brown adipose derived Bone marrow derived Secretome (novel exosome, stem cells mesenchymal stem cells growth factor/cytokine) biologics based technology PRECLINICAL MID-STAGE CLINICAL for cosm

  4. Slide 4: Experienced Leadership

    Experienced Leadership Lance Alstodt Robert Kristal Chairman & CEO Chief Financial Officer • 30+ years leading, advising and operating companies within the • 25+ years on Bay Street and Wall Street Healthcare sector • Most recently was the DOR for a Healthcare focused Investment Bank • Founder of Me

  5. Slide 5: ThermoStem, BRTX-100, BioCosmeceuticals

    DEVELOPMENT COMMERCIAL ThermoStem BRTX-100 BioCosmeceuticals Brown adipose derived Bone marrow derived Secretome (novel exosome, stem cells mesenchymal stem cells growth factor/cytokine) biologics based technology PRECLINICAL MID-STAGE CLINICAL for cosmetic applications 5

  6. Slide 6: Going Commercial: Biologics Based Cosmetic Products

    Going Commercial: Biologics Based Cosmetic Products The Market • Global Cosmetic market $63 B and growing • Global injectable market 12% CAGR 2021-2026 Est $11.9 B • Derms need differentiated product • Bundle with current procedures Key Features of Cosmetics & Manufacturing Hair Growth • cGMP ISO 7

  7. Slide 7: ThermoStem, BRTX-100, BioCosmeceuticals

    DEVELOPMENT COMMERCIAL ThermoStem BRTX-100 BioCosmeceuticals Brown adipose derived Bone marrow derived Secretome (novel exosome, stem cells mesenchymal stem cells growth factor/cytokine) biologics based technology PRECLINICAL MID-STAGE CLINICAL for cosmetic applications 7

  8. Slide 8: Robust Preclinical & Clinical Pipeline

    Robust Preclinical & Clinical Pipeline PRECLINICAL PHASE 1 PHASE 2 PHASE 3 COMMERCIAL Lumbar Phase 2 IND Spine Cervical SUBMITTED *** AUTOLOGOUS Thoracic Hips/Knees Musculoskeletal Extremities System Avascular Zones Type 2 Diabetes Metabolic Obesity ALLOGENEIC PCOS * ARDS ** Brown Adipose Stem Cells

  9. Slide 9: Chronic Lumbar Disc Disease (cLDD)

    Chronic Lumbar Disc Disease (cLDD) 258 M U.S. adult population 64.5 M American adults with chronic lower back pain prevalence 32 M American adults with diagnosed and treated disc degeneration 15 M Americans suffering pain caused by a protruding or injured disc 2.5 M Invasive Surgical Procedures per

  10. Slide 10: The Problem: Clinical & Economic

    The Problem: Clinical & Economic Conservative Surgical Treatments Treatments ORAL MEDICATION TREATMENT / OPIOIDS SPINAL FUSION SURGERY $1,000 - $2,000 / annually $110,000 INJECTION TREATMENT DISCECTOMY $8,000 / annually $20,000 - $2,000 per injection, 2 injections per treatment-semi-annual treatment

  11. Slide 11: Our Solution: BRTX-100

    Our Solution: BTRX-100 Regenerative Conservative Medicine Surgical Treatments Treatments ORAL MEDICATION TREATMENT / OPIOIDS SPINAL FUSION SURGERY $1,000 - $2,000 / annually Introduce Hypoxic Cultured $110,000 Autologous MSCs INJECTION TREATMENT DISCECTOMY $8,000 $20,000 - BRTX-100 / annually $2,000

  12. Slide 12: BRTX-100: Clinical Snapshot

    BRTX-100: Clinical Snapshot Lead investigational therapeutic product O2 30 min Autologous Hypoxic (low oxygen) Single intradiscal injection (patient’s own) cultured, bone – anticipated 30 minute cell-based biologic marrow-derived in-office procedure Prior human data provides FDA authorized Large gro

  13. Slide 13: BRTX-100: Key Differentiating Factors

    BRTX-100: Key Differentiating Factors BRTX-100 Advantages Allogeneic Autologous SOURCE uses human derived stem uses patients own • Autologous cells means low to no risk of cells (not from patient) stem cells rejection, greater safety profile (introduction - 6 million - 40 million of viral/genetic),

  14. Slide 14: BRTX-100: Positive Human Data

    BRTX-100: Positive Human Data Human data from studies of therapies similar to BRTX-100 show reduced pain, increased function, and an absence of significant safety issues with a durable response 14

  15. Slide 15: BRTX-100: Phase 2 Trial Design

    BRTX-100: Phase 2 Trial Design FDA Cleared IND 17275: Phase 2 Randomized, Controlled Study Design in Patients with cLDD Design Primary Efficacy Endpoint Patient Population • Study includes 99 subjects 12 m, F/U at 24 m • Subjects must have current (2:1 product to placebo) diagnosis of cLDD, typical

  16. Slide 16: BRTX-100: Logistical/Clinical Process

    BRTX-100: Logistical /Clinical Process Collection Collection and Shipment of Patient’s Bone Marrow and Blood to Cell Production Manufacturer 1 Clinical Site Production Thawing and Injection of 5 2 Production of BRTX-100 Hypoxic BRTX-100 into Patient’s Disc BRTX-100 Culturing of Stem Cells Production

  17. Slide 17: BRTX-100: Cleared DSMB June 2023

    BRTX-100: Cleared DSMB June 2023 Unanimous approval by the DSMB 3:1 randomization to continue trial without changes BRTX-100 is safe and well tolerated No Significant Adverse Events All 4 subjects successfully dosed VAS, ODI, SF-12, RMDQ, and FRI scores to with either 40 mil hMSCs or placebo measure

  18. Slide 18: Preliminary Phase 2 Clinical Data: Meaningful Signals

    Preliminary Phase 2 Clinical Data: Meaningful Signals “Autologous Stem Cell Therapy for Chronic Lumbar Disc Disease, Initial Phase 2 Clinical Safety and Feasibility Data of Intradiscal Injections of Hypoxic Cultured Mesenchymal Stem Cells,” presented at ORS 2024 • 4 subjects underwent successful dos

  19. Slide 19: Raw Data

    Raw Data FRI VAS Subject 1 Subject 2 Subject 3 ODI RMDQ Subject 4 19

  20. Slide 20: Relative Change

    Relative Change Relative FRI Relative VAS Subject 1 Subject 2 Subject 3 Relative ODI Relative RMDQ Subject 4 20

  21. Slide 21: ThermoStem Program: Allogeneic Cell-based Therapy

    ThermoStem Program: Allogeneic Cell-based Therapy Target Conditions: Obesity, Type 2 diabetes, Platform Program: and Metabolic disorders For the development of cell & small molecule therapies Cell Type: Brown Fat • Has been shown to regulate metabolic Migraines, depression, homeostasis in the body p

  22. Slide 22: Metabolic Program Highlights

    Metabolic Program Highlights First human stem cell derived BAT transfer Creation of first human 3D engineered artificial brown WHITE FAT adipose tissue construct (aBAT) Successful delivery of 3D aBAT construct in mouse model BEIGE FAT Transplantation of aBAT lowered blood glucose levels BROWN FAT Tr

  23. Slide 23: Metabolic Program Clinical Pathway

    Metabolic Program Clinical Pathway Initiate Phase 1/2 Clinical Trial Pre-IND Meeting Upon FDA approval commence Phase 1/2 clinical trial. with FDA Scheduling Pre-IND meeting with FDA to discuss first-in-man File DMF fast-track regulatory pathways. with FDA Expect filing a Drug Master File (“DMF”) wi

  24. Slide 24: Our Opportunities are Well-Protected

    Our Opportunities are Well-Protected PROGRAM ThermoStem INDICATION Disc / Spine Metabolic • Brown Fat Compositions and Methods • Methods and Compositions to facilitate • Human Brown Adipose Derived Stem Cells repair of avascular tissue and Uses PATENT TITLES • Surgical Methods and Compositions to •

  25. Slide 25: Scientific Advisory Board

    Scientific Advisory Board Wayne Marasco, MD, PDt Jason Lipetz, MD Harvinder Sandhu, MD Chairman of SAB Sub Committee Chairman of SAB Member Disc Advisory Board Disc Advisory Board • Principal Faculty Member of Harvard Stem • Chief of Spine Medicine for the Northwell • Orthopedic Spine Surgeon at the

  26. Slide 26: Financial Summary

    Financial Summary Common Shares 6.8 Million 1 Outstanding Cash $11.1 Million 2 Debt $0 1 As of 03/28/2024 2 As of 12/31/2023; does not include approx. net proceeds of $7.6 million from 02/06/2024 warrant exchange 26

  27. Slide 27: 2023 Accomplishments

    2023 Accomplishments BRTX cGMP Clean Room Expanded ThermoStem patent portfolio in U.S. and Japan Two Notice of Allowances Completed 4 patient Safety Run-in component for Phase 2 Announced a filing and execution of an ATM Announced Northwell Healthcare Partnership – Largest Healthcare System in the N

  28. Slide 28: Upcoming Milestones: Provide Multiple Potential Value Inflection Points

    Upcoming Milestones: Provide Multiple Potential Value Inflection Points PLATFORM PROGRAM/ACTIVITY SITUATION OVERVIEW Cell-Based Skin remodeling, facial • Regenerative Cosmetic & Aesthetic treatment to rejuvenate Secretome Derived application /hair growth skin and grow hair • Anticipate providing upd

  29. Slide 29: In Conclusion

    In Conclusion Addressing Multi-Billion Dollar Markets cGMP ISO-7 Certified Clean room with Unmet Needs Disruptive Platform Technologies in Opportunity for Key Strategic Cellular Therapy Partnerships in Cosmetic Space Strong Preliminary Data Indicative of Strong Intellectual Property Protection Posit

  30. Slide 30: 40 Marcus Drive, Suite 1 Melville, NY 11747 biorestorative.com

    40 Marcus Drive, Suite 1 Melville, NY 11747 (631) 760-8100 biorestorative.com

BioRestorative Therapies — Investor Presentation (April 2024) on 6ix